Bayer's Long Road Back: Profit Returns, Debt Falls, and One Court Date Still Holds the Key
Published on 08/05/2026 at 09:03 | Redaktion boerse-global.de
A year ago, Bayer was the stock nobody wanted to defend. Buried under a mountain of Monsanto-era debt and an endless wave of glyphosate litigation, the Leverkusen-based conglomerate looked less like a blue-chip and more like a permanent restructuring case. Twelve months on, the picture has changed dramatically: shares have gained 74.86 percent over that stretch, and Tuesday's half-year numbers suggest the operational turnaround is no longer just a narrative — it's showing up in the profit line.
The company swung to a net profit of 219 million euros in the second quarter, reversing a 199 million euro loss in the same period last year. Adjusted EBITDA came in at 2.14 billion euros, up 1.9 percent year on year, while quarterly revenue rose 2 percent to 10.9 billion euros. For the first half as a whole, sales reached 24.3 billion euros — a 3 percent increase — with adjusted EBITDA climbing 7 percent to 6.6 billion euros.
Crop Science Carries the Load
The engine room of this recovery is the agriculture division. Crop Science saw revenue advance 5.5 percent, while segment operating profit jumped 30 percent to 902 million euros, supported by an EBITDA margin of 31 percent in the first half. The tailwinds are twofold: firmer glyphosate pricing and the US Environmental Protection Agency's decision to once again permit the herbicide Dicamba. Both factors have eased concerns that regulatory pressure and price competition would cripple Bayer's core farming business.
Pharma tells a more complicated story — one of managed decline in one corner and rapid growth in another. Patent expirations continue to erode the legacy blockbusters: blood thinner Xarelto saw sales fall 42 percent, while eye drug Eylea dropped 33 percent, squeezed by biosimilar competition. The newer generation is stepping up, though. Prostate cancer treatment Nubeqa grew 66 percent, and kidney disease drug Kerendia surged 83 percent. The division's total revenue came to 4.46 billion euros, reflecting a portfolio in transition that management insists is both necessary and on track.
Should investors sell immediately? Or is it worth buying Bayer?
Debt: The Other Battlefront
For years, the balance sheet was the second anchor dragging Bayer down — a direct inheritance of the $63 billion Monsanto acquisition. That, too, is shifting. Net financial debt stood at 33.6 billion euros, but the company has now lowered its target range to 29–30 billion euros, down from a previous 32–33 billion. Two moves underpin this: private equity firm Apollo is injecting 3 billion euros into Bayer's contraception business, and the company has placed a 5 billion dollar bond.
CEO Bill Anderson, meanwhile, has pushed back against speculation of a full corporate breakup. His stated path is continued restructuring along five defined priorities rather than a structural dismantling of the group.
The Legal Calendar Still Rules
For all the operational progress, the stock's fate remains tethered to the courtroom. The US Supreme Court's late-June ruling — which determined Bayer need not add cancer warnings to Roundup labels — provided a significant tailwind and helped push the shares to a 52-week high of 53.86 euros in early July. The next milestone arrives on August 19, when a Missouri hearing will address a potential settlement of up to 7.25 billion dollars, spread over 21 years.
That settlement framework matters for investors because it offers something the previous drip-feed of individual verdicts never did: predictability. A favorable outcome could close the valuation gap that still exists — the stock trades roughly 10 percent below its recent peak. A failure, by contrast, would likely see the market quickly reprice the litigation risk.
Bayer at a turning point? This analysis reveals what investors need to know now.
Market Sentiment: Cautious Optimism
The market's response to Tuesday's numbers was constructive. Bayer shares closed the following session at 48.40 euros, up 2.07 percent, and the stock has gained nearly 31 percent since the start of the year. JPMorgan analyst Richard Vosser called the results strong and pointed to rising earnings expectations. Goldman Sachs also reaffirmed its buy rating midweek.
Still, the equity's implied volatility of 61.79 percent tells its own story: investors are not fully convinced the worst is over. The recovery has been real — a product of agricultural strength, debt discipline, and legal progress — but the August 19 hearing in Missouri remains the kind of binary event that keeps the risk premium alive. Bayer has rebuilt its foundation, but the final judgment on this comeback is still pending.
Ad
Bayer Stock: New Analysis - 5 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
